靶向抑制2型大麻素受体:减轻肾纤维化的新策略
该研究在多种肾损伤模型中观察到2型大麻素受体(CB2)主要在肾小管上皮诱导表达,CB2激活可触发基质基因表达并介导成纤维细胞和巨噬细胞活化,而CB2基因敲除小鼠在输尿管梗阻后肾损伤减轻。研究者发现新型反向激动剂XL-001,体内注射可改善梗阻和缺血再灌注模型的肾损伤、纤维化和炎症,延迟给药亦有效。
要点
- CB2在肾小管上皮诱导表达并促进肾纤维化。
- CB2基因敲除或反向激动剂XL-001可减轻肾纤维化。
- XL-001延迟给药仍可改善肾纤维化和炎症。
核心结论
- CB2是肾纤维化的致病介质,靶向抑制CB2(如XL-001)可能成为抗纤维化肾病策略。
研究设计与样本
- 研究采用多种肾损伤模型(单侧输尿管梗阻、阿霉素、缺血再灌注)、体外细胞实验、CB2基因敲除小鼠及计算机筛选与药物化学改造。
主要发现
- CB2在多种肾病模型中主要于肾小管上皮诱导表达。
- 体外强制表达CB2或CB2激动剂足以触发基质基因表达,siRNA敲低CB2可消除TGF-β1诱导的信号和纤维化反应。
- CB2介导体外成纤维细胞和巨噬细胞活化。
- CB2基因敲除小鼠在输尿管梗阻后肾损伤减轻。
- XL-001以剂量依赖方式抑制CB2过表达、CB2激动剂或TGF-β1诱导的纤维化反应,体内注射改善梗阻和缺血再灌注模型的肾损伤、纤维化和炎症,延迟给药亦有效。
临床怎么用
- XL-001作为新型CB2反向激动剂,在动物模型中展示抗纤维化潜力,但尚未进入临床,需进一步转化研究。
局限性
- 研究主要基于动物模型和体外实验,尚未在人体中验证CB2抑制的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cannabinoid receptor type 2 (CB2) is a G protein-coupled seven transmembrane receptor that transmits endogenous cannabinoid signaling. The role of CB2 in the pathogenesis of kidney injury and fibrosis remains poorly understood. Here we demonstrate that CB2 was induced, predominantly in kidney tubular epithelium, in various models of kidney disease induced by unilateral ureteral obstruction, adriamycin or ischemia/reperfusion injury. In vitro, forced expression of CB2 or treatment with a CB2 agonist was sufficient to trigger matrix gene expression, whereas knockdown of CB2 by siRNA abolished transforming growth factor-β1-induced signaling and fibrogenic responses in kidney tubular cells. CB2 also mediated fibroblasts and macrophage activation in vitro. Mice with genetic ablation of CB2 were protected against kidney injury after ureteral obstruction, validating a pathogenic role of CB2 in renal fibrosis in vivo. By using in silico screening and medicinal chemistry modifications, we discovered a novel compound, XL-001, that bound to CB2 with high affinity and selectivity and acted as an inverse agonist. Incubation with XL-001 inhibited in a dose-dependent fashion the fibrogenic response induced by CB2 overexpression, CB2 agonist or transforming growth factor-β1. In vivo, intraperitoneal injections of XL-001 ameliorated kidney injury, fibrosis and inflammation in both the obstruction and ischemia/reperfusion models. Delayed administration of XL-001 was also effective in ameliorating kidney fibrosis and inflammation. Thus, CB2 is a pathogenic mediator in kidney fibrosis and targeted inhibition with the novel inverse agonist XL-001 may provide a strategy in the fight against fibrotic kidney diseases.
引用
- Zhou L, Zhou S, Yang P, et al. Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis. Kidney Int. 2018. PMID: 30093080. doi:10.1016/j.kint.2018.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。